Headlines
Netherlands pushes for more generic drug imports from India
Published by Global Banking and Finance Review
Posted on September 5, 2025
Global Banking and Finance Review
Company
Global Banking and Finance Review is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.
Published by Global Banking and Finance Review
Posted on September 5, 2025
By Rishika Sadam and Sriparna Roy
NEW DELHI (Reuters) -The Netherlands is aiming to increase imports of Indian generic drugs into the country, as it looks to diversify its portfolio and avoid supply constraints, Dutch government officials and industry experts said at an event on Friday.
India, popularly referred to as the 'pharmacy of the world, exported $616 million worth of drugs in fiscal year 2025 to the Netherlands, making it India's seventh largest export market.
The biggest market for India is the U.S., where tariff concerns linger. India mostly exports generic drugs that are cheaper versions of popular innovative drugs.
"The Netherlands has a generic uptake of 80% for annual prescriptions... Four out of 5 medicines going to patients are generic drugs," Kayleigh van Winssen, deputy director of pharmaceutical affairs at the Netherlands ministry of health, said at the International Pharmaceutical Exhibition in New Delhi.
There are over 22,000 medicines authorized for use in the Netherlands, she noted.
The European nation encouraged Indian drug manufacturers to increase exports to the Netherlands and across therapy areas.
The Netherlands delegation said at the event that the country is looking to diversify its portfolio and reduce dependence on single drug suppliers or those with extremely high market share.
There has been a 50% drop in generic medicine registrations in the last five years, with fewer generic products in the market, according to Leon Tinke, managing director of BENU, one of the largest pharmacy chains in the Netherlands.
Under an existing agreement between India and the Netherlands, the countries have been collaborating to train inspectors to learn about the regulatory process.
"Indian inspectors (are) being trained in the Netherlands from both the national and state level...We already had a training in January and other trainings are being lined up," said Winssen.
"We are also thinking about how we can provide companies with better information," she said.
(Reporting by Rishika Sadam and Sriparna Roy in New Delhi; Editing by Shinjini Ganguli)